<DOC>
	<DOCNO>NCT02607436</DOCNO>
	<brief_summary>This prospective interventional study assess effect sarpogrelate compare aspirin Korean type 2 diabetic patient atherosclerosis .</brief_summary>
	<brief_title>Effect Sarpogrelate , Serotonin Receptor Antagonist , Coronary Artery Disease</brief_title>
	<detailed_description>Type 2 diabetes increase exponentially , arouse serious economic , social health repercussion . Also , macrovascular complication diabetes myocardial infarct stroke increase . Individuals diabetes great risk cardiovascular disease ( CVD ) , approximately two four time without diabetes . Currently , U.S. Food Drug Administration require demonstration new anti-hyperglycemic agent increase cardiovascular risk . The comprehensive multifactorial management type 2 diabetes , include control hypertension , dyslipidemia obesity , know significantly reduce risk CVD show Steno-2 study . However , anti-diabetic agent currently use clinical practice seem provide enough cardiovascular protection .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Sarpogrelate</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Serotonin Antagonists</mesh_term>
	<criteria>Type 2 diabetes HbA1c â‰¥ 6.5 % screen visit Male female 30 80 year age Coronary artery stenosis : 1075 % without evidence acute coronary syndrome No history previous myocardial infarction Systolic blood pressure / diastolic blood pressure &gt; 160/110 mmHg Congestive heart failure Allergy radiocontrast dye Allergy aspirin sarpogrelate Acute bleed History ulcer bleed GOT/GPT &gt; 100/100 Other antiplatelet medication</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>